 -- Adverum to host webcast with key opinion leaders on Sunday, May 2, 2021 at 7:00 AM PT -- REDWOOD CITY, Calif., April 16, 2021 GLOBE NEWSWIRE -- Adverum Biotechnologies, Inc. Nasdaq: ADVM, a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of additional clinical data for Cohorts 1-4 in the OPTIC clinical trial of ADVM-022 intravitreal IVT injection gene therapy in wet age-related macular degeneration wet AMD during the Association for Research in Vision and Ophthalmology ARVO 2021 Virtual Meeting. Preclinical data on ADVM-062, a novel IVT gene therapy that also utilizes Adverums proprietary vector capsid AAV.7m8, in blue cone monochromacy will also be presented. 